Sunways India Pvt Ltd. More Than 60 Years of Dedicated & Commited Effort in the Field of OPTHAMOLOGY
BRIO-T
Dry Macular Degeneration  
Composition  
Each ml contains:  
Brinzolamide IP 1.0 % w/v
Timolol Maleate IP
Eq. to Timolol 0.5% w/v
Benzalkonium Chloride Solution 0.02% v/v
(as preservative)
Aqueous base q.s
Dosage Form
Ophthalmic suspension
Category
Anti-glaucoma
Description
Brio-T ophthalmic suspension comprising of two components – Brinzolamide and Timolol maleate. Brinzolamide belongs to a class of drugs known as Carbonic Anhydrous Inhibitors. Timolol, a nonselective beta-adrenoreceptor blocking agent. These two components decrease the elevated IOP primarily by reducing aqueous humour secretion.
Indication and Usage
Brio-T is indicated to decrease intra-ocular pressure in adult patients with Open-angle glaucoma or ocular hypertension.
Dosage and Administration
As directed by the physician.
Contraindications
Brio-T Eye drops is contraindicated in patients with :
  • Hypersensitivity to the active substances, or to any of the excipients.
  • Hypersensitivity to other beta-blockers.
  • Hypersensitivity to Sulphonamides.
    		•
    Warnings and Precautions
    Hypersensitivity reactions common to all sulphonamide derivatives can occur in patients receiving brinzolamide and timolol ophthalmic suspension as it is absorbed systematically.

    Storage
    Store in a dry place at a temperature not exceeding 30°C. Do not freeze. Keep out of reach of children. Replace cap immediately after use. Use this suspension within one month after opening the container.

    Presentation
    Brio-T eye drops is supplied in a 5ml sterile plastic bottle.